Kaposi Sarcoma in case of solid organ transplantation

Kaposi sarcoma (KS) is a soft tissue cancer that is related to several intrinsic and environ­mental factors. In the general population, KS is an extremely rare tumor, however, the risk of its development is substantially increased in immune compromised patients including patients with acquired immune deficiency syndrome (AIDS) and solid organ recipients. Genetic predisposition, seropositivity for human herpes virus type HHV, and increased HHV prevalence in the general population are some proposed factors for the development of KS. Middle East is reported as a highly prevalent region for the incidence of post-transplant KS, reports from Saudi Arabia, Egypt and Turkey indicate a high incidence of this disease. Kaposi sarcoma was first described by Moritz Kaposi in the 1870, the disease was a medical curiosity in Europe and the United States until the acquired immunodeficiency syndrome was recognized in 1981.

 

    Related Conference of Kaposi Sarcoma in case of solid organ transplantation

    April 03-04, 2023

    International Conference on Aging and Gerontology

    Rome, Aland Islands
    May 03-04, 2023

    16th World Congress on Stem Cell Research

    Paris, France
    May 03-04, 2023

    Global Conference on Cell and Gene Therapy

    Paris, France
    June 09-10, 2023

    10th World Congress on Epigenetics and Chromosome

    Valencia, Spain
    June 28-29, 2023

    27th Global Congress on Biotechnology

    Toronto, Canada
    September 25-26, 2023

    19th Global Summit on Stem Cell & Regenerative Medicine

    Zurich, Switzerland
    October 19-20, 2023

    5th Annual summit on Cell Signaling and Cancer Therapy

    Montreal, Canada
    December 07-08, 2023

    17th International Conference on Genomics & Pharmacogenomics

    San Francisco, USA

    Kaposi Sarcoma in case of solid organ transplantation Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in